(616 Kb) Access

: Patients in clinical trials were generally younger, with a mean age of 58 compared to 61 in this real-world group.

Toxicities and outcomes of 616 ibrutinib-treated patients in ... - PMC (616 KB)

: Despite the high rate of stopping, the overall survival and progression-free survival (estimated at 35 months) remained excellent. Real-World vs. Clinical Trials : Patients in clinical trials were generally younger,

Provide a breakdown of the used by the researchers in this study. Which of these would be most helpful for you? Real-World vs

The researchers analyzed a large group of 616 patients with who were treated with ibrutinib. The goal was to see if the high success rates found in clinical trials were mirrored in everyday medical practice across various hospitals. Key Findings and Statistics

: A major finding was that 41% of patients stopped taking ibrutinib within a median of 17 months.

: For those who stopped the medication, the median time until they did so was only 7 months .